These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10922401)

  • 1. Cutting copper curbs angiogenesis, studies show.
    Vanchieri C
    J Natl Cancer Inst; 2000 Aug; 92(15):1202-3. PubMed ID: 10922401
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiangiogenic therapy through copper chelation.
    Sproull M; Brechbiel M; Camphausen K
    Expert Opin Ther Targets; 2003 Jun; 7(3):405-9. PubMed ID: 12783576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BIOMEDICINE. Targeting copper to treat breast cancer.
    Garber K
    Science; 2015 Jul; 349(6244):128-9. PubMed ID: 26160923
    [No Abstract]   [Full Text] [Related]  

  • 4. Copper deficiency as an anti-cancer strategy.
    Goodman VL; Brewer GJ; Merajver SD
    Endocr Relat Cancer; 2004 Jun; 11(2):255-63. PubMed ID: 15163301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control of copper status for cancer therapy.
    Goodman VL; Brewer GJ; Merajver SD
    Curr Cancer Drug Targets; 2005 Nov; 5(7):543-9. PubMed ID: 16305350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.
    Brewer GJ; Merajver SD
    Integr Cancer Ther; 2002 Dec; 1(4):327-37. PubMed ID: 14664727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A requirement for copper in angiogenesis.
    Harris ED
    Nutr Rev; 2004 Feb; 62(2):60-4. PubMed ID: 15080367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma.
    Brem S; Grossman SA; Carson KA; New P; Phuphanich S; Alavi JB; Mikkelsen T; Fisher JD;
    Neuro Oncol; 2005 Jul; 7(3):246-53. PubMed ID: 16053699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of copper in tumour angiogenesis--clinical implications.
    Nasulewicz A; Mazur A; Opolski A
    J Trace Elem Med Biol; 2004; 18(1):1-8. PubMed ID: 15487757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenesis. A boost for tumor starvation.
    Marx J
    Science; 2003 Jul; 301(5632):452-4. PubMed ID: 12881543
    [No Abstract]   [Full Text] [Related]  

  • 11. Anticopper therapy against cancer and diseases of inflammation and fibrosis.
    Brewer GJ
    Drug Discov Today; 2005 Aug; 10(16):1103-9. PubMed ID: 16182195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.
    Weller M; Yung WK
    Neuro Oncol; 2013 Aug; 15(8):971. PubMed ID: 23864129
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 14. [Wilsons disease].
    Mareček Z; Brůha R
    Vnitr Lek; 2013 Jul; 59(7):578-83. PubMed ID: 23909262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enigma of a rapid introduction of antiangiogenic therapy with bevacizumab in glioblastoma: a new era in the treatment of malignant brain tumours?
    Henriksson R; Bergström P; Johansson M; Sandström M
    Acta Oncol; 2009; 48(1):6-8. PubMed ID: 18932097
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of avastin in the management of recurrent glioblastoma.
    Sweet JA; Feinberg ML; Sherman JH
    Neurosurg Clin N Am; 2012 Apr; 23(2):331-41, x. PubMed ID: 22440876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells.
    Yoshii J; Yoshiji H; Kuriyama S; Ikenaka Y; Noguchi R; Okuda H; Tsujinoue H; Nakatani T; Kishida H; Nakae D; Gomez DE; De Lorenzo MS; Tejera AM; Fukui H
    Int J Cancer; 2001 Dec; 94(6):768-73. PubMed ID: 11745476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concerns and challenges regarding tailored anti-angiogenic therapy in cancer.
    Roukos DH; Tzakos A; Zografos G
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1413-6. PubMed ID: 19828000
    [No Abstract]   [Full Text] [Related]  

  • 19. [Wilson disease in 2003].
    Szalay F
    Orv Hetil; 2003 Dec; 144(50):2451-8. PubMed ID: 15067983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer.
    Henry NL; Dunn R; Merjaver S; Pan Q; Pienta KJ; Brewer G; Smith DC
    Oncology; 2006; 71(3-4):168-75. PubMed ID: 17641535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.